Impairment of the antiproliferative effect of glucocorticosteroids by 11β-hydroxysteroid dehydrogenase type 2 overexpression in MCF-7 breast-cancer cells

Hormone and Metabolic Research

Volumn 36, Issue 7, 2004, Pages 437-444

  Lipka, C ^a,c   Mankertz, J ^a   Fromm, M ^a   Lubbert H ^a   Buhler H ^b   Kuhn W ^a   Ragosch, V ^a   Hundertmark, S ^a,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c ASKLEPIOS KLINIK ALTONA   (Germany)

Author keywords

Breast cancer; Glucocorticosteroids

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ALDOSTERONE; CORTICOSTERONE; DEHYDROCORTICOSTERONE; DEXAMETHASONE; GLUCOCORTICOID; HYDROCORTISONE; PREDNISOLONE; TRITIUM;

ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REDUCTION; RNA TRANSLATION; WILD TYPE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ADENOCARCINOMA; BREAST NEOPLASMS; CELL DIVISION; CLONING, MOLECULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOCORTICOIDS; HUMANS; RECEPTORS, GLUCOCORTICOID; RECEPTORS, MINERALOCORTICOID; TRANSFECTION; TUMOR CELLS, CULTURED;

CUCUMBER MOSAIC VIRUS; MINK CELL FOCUS-FORMING VIRUS; VECTORS;

EID: 4344705188     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-825724     Document Type: Article

References (62)

1. Lippman M, Bolan G, Huff K. The effects of glucocorticoids and progesterone on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 1976; 36: 4602-4609
2. Osborne CK, Monaco ME, Kahn CR, Huff K, Bronzert D, Lippman ME. Direct inhibition of growth and antagonism of insulin action by glucocorticoids in human breast cancer cells in culture. Cancer Res 1979; 39: 2422-2428
3. Zhou F, Bouillard B, Pharaboz-Joly MO, Andre J. Non-classical antiestrogenic actions of dexamethasone in variant MCF-7 human breast cancer cells in culture. Mol Cell Endocrinol 1989; 66: 189-197
4. Poulin R, Baker D, Poirier D, Labrie F. Multiple actions of synthetic 'progestins' on the growth of ZR-75-1 human breast cancer cells: an in vitro model for the simultaneous assay of androgen, progestin, estrogen, and glucocorticoid agonistic and antagonistic activities of steroids. Breast Cancer Res Treat 1991; 17: 197-210
5. Goya L, Maiyar AC, Ge Y, Firestone GL Glucocorticoids induce a G1/GO cell cycle arrest of Con8 rat mammary tumor cells that is synchronously reversed by steroid withdrawal or addition of transforming growth factor-alpha. Mol Endocrinol 1993; 7: 1121-1132
6. Penning TM, Ricigliano JW. Mechanism based inhibition of hydroxysteroid dehydrogenases. J Enzyme Inhib 1991; 5: 165-198
7. Roy AK. Regulation of steroid hormone action in target cells by specific hormone-inactivating enzymes. Proc Soc Exp Biol Med 1992; 199: 265-272
8. Hundertmark S, Ragosch V, Schein B, Buhler H, Lorenz U, Fromm M, Weitzel HK. Gestational age dependence of 11 beta-hydroxysteroid dehydrogenase and its relationship to the enzymes of phosphatidylcholine synthesis in lung and liver of fetal rat. Biochim Biophys Acta 1994; 1210: 348-354
9. Seckl JR. 11 beta-hydroxysteroid dehydrogenase isoforms and their implications for blood pressure regulation. Eur J Clin Invest 1993; 23: 589-601
10. Chapman KE, Kotelevtsev YV, Jamieson PM, Williams LJ, Mullins JJ, Seckl JR. Tissue-specific modulation of glucocorticoid action by the 11 beta-hydroxysteroid dehydrogenases. Biochem Soc Trans 1997; 25: 583-587
11. Rabbitt EH, Lavery GG, Walker EA, Cooper MS, Stewart PM, Hewison M. Prereceptor regulation of glucocorticoid action by 11 beta-hydroxysteroid dehydrogenase: a novel determinant of cell proliferation. FASEB J 2002; 16: 36-44
12. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR, Mullins JJ. 11 beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 1997; 94: 14924-14929
13. Monder C, Shackleton CH. 11 beta-Hydroxysteroid dehydrogenase: fact or fancy? Steroids 1984; 44: 383-417
14. Brown RW, Chapman KE, Edwards CR, Seckl JR. Human placental 11 beta-hydroxysteroid dehydrogenase: evidence for and partial purification of a distinct NAD-dependent isoform. Endocrinology 1993; 132: 2614-2621
15. Stewart PM, Mason JI. Cortisol to cortisone: glucocorticoid to mineralocorticoid. Steroids 1995; 60: 143-146
16. Jamieson PM, Chapman KE, Edwards CR, Seckl JR. 11 beta-hydroxysteroid dehydrogenase is an exclusive 11 beta-reductase in primary cultures of rat hepatocytes: effect of physiochemical and hormonal manipulations. Endocrinology 1995; 136: 4754-4761
17. Hammami MM, Siiteri PK. Regulation of 11 beta-hydroxysteroid dehydrogenase activity in human skin fibroblasts: enzymatic modulation of glucocorticoid action. J Clin Endocrinol Metab 1991; 73: 326-334
18. Low SC, Chapman KE, Edwards CR, Seckl JR. 'Liver type' 11 beta-hydroxysteroid dehydrogenase cDNA encodes reductase but not dehydrogenase activity in intact mammalian COS-7 cells. J Mol Endocrinol 1994; 13: 167-174
19. Rajan V, Chapman KE, Lyons V, Jamieson P, Mullins JJ, Edwards CR, Seckl JR. Cloning, sequencing and tissue-distribution of mouse 11 beta-hydroxysteroid dehydrogenase-1 cDNA. J Steroid Biochem Mol Biol 1995; 52: 141-147
20. Voice MW, Seckl JR, Edwards CR, Chapman KE. 11 beta-hydroxysteroid dehydrogenase type 1 expression in 2S FAZA hepatoma cells is hormonally regulated: a model system for the study of hepatic glucocorticoid metabolism. Biochem J 1996; 317: 621-625
21. Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS. Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 1994; 105: R11-R17
22. Stewart PM, Murry BA, Mason JI. Human kidney 11 beta-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type I isoform. J Clin Endocrinol Metab 1994; 79: 480-484
23. Brown RW, Chapman KE, Murad P, Edwards CR, Seckl JR. Purification of 11 beta-hydroxysteroid dehydrogenase type 2 from human placenta utilizing a novel affinity labelling technique. Biochem J 1996; 313: 997-1005
24. Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Su tanto WS, de Kloet ER, Monder C. Localisation of 11 beta-hydroxysteroid dehydrogenase - tissue specific protector of the mineralocorticoid receptor. Lancet 1988; 2: 986-989
25. Funder JW, Pearce PT, Smith R, Smith Al. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988; 242: 583-585
26. Murphy BE. Ontogeny of cortisol-cortisone interconversion in human tissues: a role for cortisone in human fetal development. J Steroid Biochem 1981; 14: 811-817
27. Seckl JR, Benediktsson R, Lindsay RS, Brown RW. Placental 11 beta-hydroxysteroid dehydrogenase and the programming of hypertension. J Steroid Biochem Mol Biol 1995; 55: 447-455
28. Hundertmark S, Buhler H, Rudolf M, Weitzel HK, Ragosch V. Inhibition of 11 beta-hydroxysteroid dehydrogenase activity enhances the antiproliferative effect of glucocorticosteroids on MCF-7 and ZR-75-1 breast cancer cells. J Endocrinol 1997; 155: 171-180
29. Takahashi K, Shibata S, Yano S, Harada M, Saito H, Tamura Y, Kumagai A. Chemical modification of glycyrrhetinic acid in relation to the biological activities. Chem Pharm Bull (Tokyo) 1980; 28: 3449-3452
30. Stewart PM, Wallace AM, Valention R, Burt D, Shackleton CH, Edwards CR. Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987; 2: 821-824
31. Monder C, Stewart PM, Lakshmi V, Valentine R, Burt D, Edwards CR. Licorice inhibits corticosteroid 11 beta-dehydrogenase of rat kidney and liver: in vivo and in vitro studies. Endocrinology 1989; 125: 1046-1053
32. Hundertmark S, Buhler H, Ragosch V, Dinkelborg L, Arabin B, Weitzel HK. Correlation of surfactant phosphatidylcholine synthesis and 11 beta-hydroxysteroid dehydrogenase in the fetal lung. Endocrinology 1995; 136: 2573-2578
33. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provengano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. Measurement of protein using bicinchoninic acid. Analytical Biochemistry 1985; 150: 76-85
34. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63
35. Quirk SJ, Slattery J, Funder JW. 11 beta-hydroxysteroid dehydrogenase activity in the mammary gland. J Steroid Biochem 1990; 35: 623-625
36. Quirk SJ, Slattery JA, Funder JW. Epithelial and adipose cells isolated from mammary glands of pregnant and lactating rats differ in 11 beta-hydroxysteroid dehydrogenase activity. J Steroid Biochem Mol Biol 1990; 37: 529-534
37. Yang K, Khalil MW, Strutt BJ, Killinger DW. 11 beta-hydroxysteroid dehydrogenase 1 activity and gene expression in human adipose stromal cells: effect on aromatase activity. J Steroid Biochem Mol Biol 1997; 60: 247-253
38. Sasano H, Frost AR, Saitoh R, Matsunaga G, Nagura H, Krozowski ZS, Silverberg SG. Localization of mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase type 11 in human breast and its disorders. Anticancer Res 1997; 17: 2001-2007
39. Nath N, Lakshmi V, Rosenthal JC. Presence of 11 beta-hydroxysteroid dehydrogenase enzyme in the human prostate tumor cell line LNCaP. Prostate 1993; 23: 225-233
40. Suzuki S, Suzuki T, Tsubochi H, Koike K, Tateno H, Krozowski ZS, Sasano H. Expression of 11 beta-hydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor in primary lung carcinomas. Anticancer Res 2000; 20: 323-328
41. Takahashi K, Sasano H, Fukushima K, Hirasawa G, Miura H, Sasaki I, Matsuno S, Krozowski ZS, Nagura H. 11 beta-hydroxysteroid dehydrogenase type 11 in human colon: a new marker of fetal development and differentiation in neoplasms. Anticancer Res 1998; 18: 3381-3388
42. Marandi A, Monder C. Inhibition by glycyrrhetinic acid of rat tissue 11 beta-hydroxysteroid dehydrogenase in vivo. Steroids 1993; 58: 153-156
43. Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR. Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987; 2: 821-824
44. Wang ZY, Nixon DW. Licorice and cancer. Nutr Cancer 2001; 39: 1-11
45. Diederich S, Eigendorff E, Burkhardt P, Quinkler M, Bumke-Vogt C, Rochel M, Seidelmann D, Esperling P, Oelkers W, Bahr V. 11 beta-hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids. J Clin Endocrinol Metab 2002; 87: 5695-5701
46. Pompei R, Pani A, Flore O, Marcialis MA, Loddo B. Antiviral activity of glycyrrhizic acid. Experientia 1980; 36: 304
47. Badam L. Ammonium salt of glycyrrhizic acid as an antiviral. Natl Med J India 1997; 10: 98
48. Yano S, Harada M, Watanabe K, Nakamaru K, Hatakeyama Y, Shibata S, Takahashi K, Mori T, Hirabayashie K, Takeda M. Antiulcer activities of glycyrrhetinic acid derivates in experimental gastric lesions models. Chem Pharm Bull 1989; 37: 2500-2504
49. Okimasu E, Moromizato Y, Watanabe S, Sasaki J, Shiraishi N, Morimoto YM, Miyahara M, Utsumi K. Inhibition of phospholipase A2 and platelet aggragation by glycyrrhizin, an antiinflammation drug. Acta Med Okayama 1983; 37: 385-391
50. Kim DH, Hong SW, Kim BT, Bae EA, Park HY, Han MJ. Biotransformation of glycyrrhizin by human intestinal bacteria and its relation to biological activities. Arch Pharm Res 2000; 23: 172-177
51. Agarwal R, Wang ZY, Mukhtar H. Inhibition of mouse skin tumor-initiating activity of DMBA by chronic oral feeding of glycyrrhizin in drinking water. Nutr Cancer 1991; 15: 187-193
52. Abe H, Ohya N, Yamamoto KF, Shibuya T, Arichi S, Odashima S. Effects of glycyrrhizin and glycyrrhetinic acid on growth and melanogenesis in cultured B16 melanoma cells. Eur J Cancer Clin Oncol 1987; 23: 1549-1555
53. Rossi T, Galatulas I, Bossa R, Tampieri A, Tartoni P, Baggio G, Rub AI, Castelli M. Influence of glycyrrhizin on the evolution and respiration of Ehrlich ascites tumour cells. In Vivo 1995; 9: 183-186
54. Ge S, Lan X, Satoru S. The inhibiting effect of glycyrrhizin on proliferation of the mice submandibular gland flbrosarcoma cell line in vitro. Zhonghua Kou Ojang Yi Xue Za Zhi 1998; 33: 341-343
55. Stormer FC, Reistad R, Alexander J. Glycyrrhizic acid in liquorice - evaluation of health hazard. Food Chem Toxicol 1993; 31: 303-312
56. Armanini D, Lewicka S, Pratesi C, Scali M, Zennaro MC, Zovato S, Gottardo C, Simoncini M, Spigariol A, Zampollo V. Further studies on the mechanism of the mineralocorticoid action of licorice in humans. J Endocrinol Invest 1996; 19: 624-629
57. Buhler H, Perschel FH, Fitzner R, Hierholzer K. Endogenous inhibitors of 11 beta-OHSD: existence and possible significance. Steroids 1994; 59: 131-135
58. Morita H, Zhou M, Foecking MF, Gomez-Sanchez EP, Cozza EN, Gomez-Sanchez CE. 11 beta-Hydroxysteroid dehydrogenase type 2 complementary deoxyribonucleic acid stably transfected into Chinese hamster ovary cells: specific inhibition by 11 alpha-hydroxyprogesterone. Endocrinology 1996; 137: 2308-2314
59. Souness GW, Morris DJ. 11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta-hydroxysteroid dehydrogenase, possess hypertensiogenic activity in the rat. Hypertension 1996; 27: 421-425
60. Seeger H, Wallwiener D, Mueck AO. The effect of progesterone and synthetic progestins on serum- and estriol-stimulated proliferation of human breast cancer cells. Horm Met Res 2003; 35: 76-80
61. Flötotto T, Djahansouzi S, Gläser M, Hanstein B, Niederacher D, Brumm C, Beckmann MW. Hormones and hormone antagonists: mechanisms of action in carcinogenesis of endometrial and breast cancer. Horm Met Res 2001; 33: 451-457
62. Alvaraz-Vasquez RB, Axelrod D, Frenkel K, Newman MC, Sepkovic DW, Bradlow HL, Zumoff B. Influence of postmenopausal hormone replacement therapy on an estrogen metabolite biomarker of risk for breast cancer. Horm Met Res 2003; 35: 358-361